A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
A study highlight the importance of extending healthspans, not just lifespans and especially as life expectancy rises and demographics shift. Biological aging or the healthspan-lifespan gap (LHG) comes with a great cost burden to society, including potentially rising health care costs (also depending on types and costs of treatments). Scientists have noted that "[c]hronic diseases of aging are increasing and are inflicting untold costs on human quality of life". Further reasons to prioritize healthspans as much as lifespans include global quality of life or wellbeing. A scientific review concludes that accumulating data suggests dietary restriction (DR) – mainly intermittent fasting and caloric restriction – results in many of the same beneficial changes in adult humans as in studied organisms, potentially increasing health- and lifespan. A review published a few days later provides an overview of DR as an intervention and develops a framework for a proposed field of "precision nutrigeroscience". A study published a few days later identifies circadian-regulated autophagy as a critical contributor to intermittent time-restricted fasting-mediated lifespan extension in Drosophila and suggests that only certain forms of and/or combinations with intermittent fasting – intervals during which no food but only e.g. water and tea/coffee are ingested – may be effective beyond the benefits of healthy body weight. Scientists show that and how the flavonoid Procyanidin C1 of the antioxidant grape seed extract increases the health- and lifespan of mice.
==== Human Resource Management ==== A practical application of positive psychology is to assist individuals and organizations in identifying strengths so as to increase and sustain well-being. Therapists, counselors, coaches, various psychological professionals, HR departments, business strategists, and others, are using new methods and techniques to broaden and build upon the strengths of a wide population of individuals. This includes those not suffering from mental illness or disorder.
=== Precursors to chlorinated cyanurates === Cyanuric acid is mainly used as a precursor to N-chlorinated cyanurates, which are used to disinfect water. The dichloro derivative is prepared by direct chlorination:
Sources: en.wikipedia.org
=== Gower 1959 and Coventry 1964 === Heseltine contested the safe Labour seat of Gower at the October 1959 general election. He had been the only applicant for the Conservative (technically, Conservative and National Liberal) candidacy. He would at times attend Labour meetings and attempt to heckle the speakers, including Aneurin Bevan and the Labour candidate Ifor Davies, whom he kept trying to challenge to a debate. He obtained plenty of publicity in the local paper and obtained a swing to the Conservatives slightly better than the national average. In 1961 Heseltine was one of 29 applicants—of whom half were interviewed—for the Conservative candidacy in the marginal constituency of Coventry North. He clinched the selection after bringing his fiancée Anne Williams to the meeting. He got on well with the incumbent Labour member Maurice Edelman (whose daughter was a friend of Anne Heseltine, as she became in 1962) and they met for dinner sometimes during the campaign. Many of his Oxford contemporaries had already entered Parliament, but, to his disappointment, in the 1964 general election he was defeated by 3,530 votes. The swing to Labour was slightly less than the national average.
=== Mechanically interlocked molecular architectures === Mechanically interlocked molecular architectures consist of molecules that are linked only as a consequence of their topology. Some non-covalent interactions may exist between the different components (often those that were used in the construction of the system), but covalent bonds do not. Supramolecular chemistry, and template-directed synthesis in particular, is key to the efficient synthesis of the compounds. Examples of mechanically interlocked molecular architectures include catenanes, rotaxanes, molecular knots, molecular Borromean rings, 2D [c2]daisy chain polymer and ravels.
== Functions == The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This growth factor is a high affinity, heparin dependent ligand for FGFR4. Expression of this gene was detected only in fetal but not adult brain tissue. Synergistic interaction of the chick homolog and Wnt-8c has been shown to be required for initiation of inner ear development. The orthologous protein in mouse is FGF15, which shares about 50% amino acid identity and has similar functions. Together they are often referred to as FGF15/19. FGF19 has important roles as a hormone produced in the ileum in response to bile acid absorption. Bile acids bind to the farnesoid X receptor (FXR), stimulating FGF19 transcription. Several FXR / bile acid response elements have been identified in the FGF19 gene. Human FGF19 transcripts have been shown to be stimulated approximately 300-fold by physiological concentrations of bile acids including chenodeoxycholic acid, glycochenodeoxycholic acid and obeticholic acid in explants of ileal mucosa. FGF19 regulates new bile acid synthesis, acting through the FGFR4/Klotho-β receptor complexes in the liver to inhibit CYP7A1. FGF19 also has metabolic effects, affecting glucose and lipid metabolism when used in experimental mouse models.
=== Atrial myxoma === Myxomas are usually located in either the left or right atrium of the heart; about 86 percent occur in the left atrium. Myxomas are typically pedunculated, with a stalk that is attached to the interatrial septum. The most common location for attachment of the stalk is the fossa ovalis region of the interatrial septum. An atrial myxoma may create an extra heart sound, audible to auscultation just after S2. It is most seen on echocardiography, as a pedunculated mass that is heterogeneous in appearance. A left atrial myxoma will cause an increase in pulmonary capillary wedge pressure. The differential diagnosis include other cardiac tumors such as lipomas and rhabdomyomas (and rarely teratomas). These other tumors of the heart are typically not pedunculated, however, and are more likely to infiltrate the muscle of the heart. Cardiac magnetic resonance imaging (MRI) can help non-invasively diagnose cardiac tumors. However, diagnosis usually requires examination of a tissue sample by a pathologist.
Sources: en.wikipedia.org
== Other animals == Bovine somatotropin occurs in the pituitary of cattle and differs in structure from human pituitary growth hormone and is biologically inactive in the human being. Bovine somatotropin aids in regulating the amount of milk produced. Recombinant bovine somatotropin (rBST) is a hormone that is injected in cows that increases milk production.
The uprising had a significant effect on the decisions in Versailles that granted Poland not only the area won by the insurrectionists but also major cities with a significant German population like Bydgoszcz (Bromberg), Leszno (Lissa) and Rawicz (Rawitsch), as well as the lands of the Polish Corridor, which were also part of the Polish–Lithuanian Commonwealth before the First Partition of Poland in 1772 and connected Poland to the Baltic Sea. Germany's territorial losses following the Treaty of Versailles incited German revanchism, and created unresolved problems such as the status of the independent Free City of Danzig and of the Polish Corridor between East Prussia and the rest of Germany. This revanchism was not a popular political idea in the Weimar Republic. Attending to these issues was part of Adolf Hitler's political platform, but failed to gain any traction in the 1920s. The idea was relegated to the political margins, until the Nazis seized power. Nevertheless, Nazi Germany effectively recognised Poland's new borders in the German–Polish declaration of non-aggression of 1934, which normalised relations between the two countries. However, after the death of Polish leader Józef Piłsudski (who was admired by Hitler), the German Anschluss with Austria and the German occupation of Czechoslovakia, Hitler unilaterally withdrew from the German-Polish Non-Aggression Pact and invaded Poland in 1939, which led to the outbreak of World War II.
=== Contrast agents, bioimaging === Functionalized and surfactant dispersed graphene solutions have been designed as blood pool MRI contrast agents. Further, iodine and manganese incorporating graphene nanoparticles have served as multimodal MRI-computerized tomograph (CT) contrast agents. Graphene micro- and nano-particles have served as contrast agents for photoacoustic and thermoacoustic tomography. Graphene has also been reported to be efficiently taking up cancerous cells thereby enabling the design of drug delivery agents for cancer therapy. Graphene nanoparticles of various morphologies such as graphene nanoribbons, graphene nanoplatelets and graphene nanoonions are non-toxic at low concentrations and do not alter stem cell differentiation suggesting that they may be safe to use for biomedical applications.
=== Books === Kierkegaard: Construction of the Aesthetic (1933) Dialectic of Enlightenment (with Max Horkheimer, 1944) Composing for the Films (1947) Philosophy of New Music (1949) The Authoritarian Personality (1950) Minima Moralia: Reflections from Damaged Life (1951) In Search of Wagner (1952) Prisms (1955) Against Epistemology: A Metacritique; Studies in Husserl and the Phenomenological Antinomies (1956) Dissonanzen. Musik in der verwalteten Welt (1956) Notes to Literature I (1958) Sound Figures (1959) Mahler: A Musical Physiognomy (1960) Notes to Literature II (1961) Introduction to the Sociology of Music (1962) Hegel: Three Studies (1963) Critical Models: Interventions and Catchwords (1963) Quasi una Fantasia (1963) The Jargon of Authenticity (1964) Night Music: Essays on Music 1928–1962 (1964) Negative Dialectics (1966) Alban Berg: Master of the Smallest Link (1968) Critical Models: Interventions and Catchwords (1969) Posthumously published
Glutathione synthetase (GSS) (EC 6.3.2.3) is the second enzyme in the glutathione (GSH) biosynthesis pathway. It catalyses the condensation of gamma-glutamylcysteine and glycine, to form glutathione. Glutathione synthetase is also a potent antioxidant. It is found in many species including bacteria, yeast, mammals, and plants. In humans, defects in GSS are inherited in an autosomal recessive way and are the cause of severe metabolic acidosis, 5-oxoprolinuria, increased rate of haemolysis, and defective function of the central nervous system. Deficiencies in GSS can cause a spectrum of deleterious symptoms in plants and human beings alike. In eukaryotes, this is a homodimeric enzyme. The substrate-binding domain has a three-layer alpha/beta/alpha structure. This enzyme utilizes and stabilizes an acylphosphate intermediate to later perform a favorable nucleophilic attack of glycine.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.